Publications

Crenezumab exposure-response across AD endpoints supports a higher dose for Phase 3

Polhamus D, Rogers J, Paul R, Kshirsagar S, Sahasranaman S, Jin JY, Quartino AL.

Clinical Trials on Alzheimer’s Disease (CTAD).

December 2016


© 2016 Metrum Research Group LLC